Moderna shares fall 5.17% intraday after analyst downgrades and pipeline cuts spark profit concerns.

Moderna, Inc. (MRNA) fell 5.17% intraday amid mixed but net-negative news developments. Analyst downgrades and revised price targets, including a consensus Hold rating with a $32.67 average target implying a 23.4% downside, weighed on sentiment. Additionally, the company announced the cancellation of three mRNA vaccine programs and secured a $1.5 billion loan to extend liquidity, signaling strategic pruning of its pipeline and reliance on non-dilutive financing. While the loan and $140 million U.S. manufacturing investment were viewed as positive for near-term stability, ongoing analyst skepticism—such as RBC lowering its target to $25 and Barclays cutting to $25—underscored concerns over long-term growth and profitability. The intraday decline reflects market reaction to a balance of risk mitigation measures versus reduced pipeline potential and tempered analyst expectations.